Recently, I saw an analysis of McKinsey's current status, opportunities, and challenges in cancer treatment. This article points out that there will be five major trends in cancer treatment in the future, namely, smaller populations, shorter product lifespan, more popular combination therapy, value from blind treatment to prevention, transfer of precision treatment, and the emergence of new treatment/diagnostic techniques. Along with these trends there will be new market opportunities, early diagnosis, new treatments (such as CAR-T, RNA, DNA therapy), precision treatments (such as new antigens, autologous cell therapy), and new disease monitoring technologies (such as liquid cDNA monitoring). Other fields will grow rapidly. Of course, there will be many challenges, such as how the regulatory payment department is oriented in a complex and rapidly changing environment, how to use big data to refine effective knowledge, the targeted delivery of new therapies, and the difficulty of recruiting patients. This article predicts that after 10 years, cancer treatment will be very different from the present.
Drug source analysis
Tumor is now the main direction of basic research in life sciences and the most important business of the pharmaceutical industry. The total market now exceeds $100 billion and is expected to reach $160 billion by 2020. Cancer treatment is undergoing rapid and profound changes, and all participants need to understand the trend in time to follow the historical trend, otherwise you may not be able to get a share of the market even though this market is very large.
The rapid shortening of the product life mentioned in the article is an important reminder to the pharmaceutical industry. Twenty years ago, HER2 antibody Herceptin was listed on the market for a small molecule competition, Tykerb, and the latest class of anti-cancer PARP inhibitors may have five similar drugs in four years. In fact, Tykerb never poses a threat to Herceptin. After the failure of ALTTO, it basically quits. The real competitor of Herceptin is Roche's own HER2-ADC drug Kadcyla and HER2/HER3 dimerization inhibitor Perjeta.
A variety of factors lead to this change. 20 years ago, antibody drugs and targeted therapies were new things, and there were not many companies that believed in the ability to participate. At that time, patient participation was not as positive as it is now, and information dissemination was not as smooth as it was now because there was no network. When Slamon recruited Herceptin's first patient, the man said that he would wait until the next day when he was preparing for the family's last vacation in Mexico. As a result, Slamon called her to participate in the trial on the day of her departure to touch the patient. Still 20 years later. Of course, other diseases or better control, or the technology is too immature, or too difficult to pay to drive the capital to the tumor.
Another important function of amino acids is to provide energy to the human body. Normally, a healthy body on a general diet will use carbohydrates as its main fuel, but when the main source is depleted due to strenuous exercise, protein and amino acids can be used as a last resort. Amino acids also play an important role in food taste. Protein doesn't have much taste, but each amino acid has its own taste, and combining them is one of the important factors that define the taste of food
Amino Acid,Asn Amino Acid,Leucine Powder,Food Grade L-Tryptophan
YT(Xi'an) Biochem Co., Ltd. , https://www.ytlinkherb.com